Identification of ovarian antibodies by immunofluorescence, enzyme-linked immunosorbent assay or immunoblotting in premature ovarian failure

• Published in: Human reproduction (Oxford) Vol. 12; no. 12; pp. 2617 - 2622
• Main Authors: Wheatcroft, N J, Salt, C, Milford-Ward, A, Cooke, I D, Weetman, A P
• Format: Journal Article
• Language: English
• Published: Oxford Oxford University Press 01.12.1997
• Subjects: Adult; Autoantibodies - blood; Autoantigens - immunology; Autoimmune Diseases - immunology; Biological and medical sciences; Enzyme-Linked Immunosorbent Assay; Female; Female genital diseases; Fluorescent Antibody Technique, Indirect; Gynecology. Andrology. Obstetrics; Humans; Immunoblotting; Medical sciences; Microsomes - immunology; Middle Aged; Muscle, Skeletal - immunology; Non tumoral diseases; Ovary - immunology; Ovary - ultrastructure; Primary Ovarian Insufficiency - immunology; Endocrinopathy; Autoimmunity; Human; Antibody; Idiopathic; Autoantibody; Autoimmune disease; Indirect immunofluorescence; Female genital diseases; Immunological method; Ovarian diseases; Ovary; Ovarian failure; Female genital system; Immunoblotting assay; Female; Diagnosis; ELISA assay
• ISSN: 0268-1161; 1460-2350
• DOI: 10.1093/humrep/12.12.2617

The development of new techniques for the detection of ovarian antibodies has challenged early concepts about the rarity of ovarian antibodies in idiopathic premature ovarian failure (POF), but few attempts have been made to compare results between assays. We have sought to define the prevalence of ovarian autoimmunity in a group of 30 idiopathic POF patients compared to a group of 12 patients with POF plus an associated autoimmune disease and a group of 38 controls, using an enzyme-linked immunosorbent assay (ELISA) and indirect immunofluorescence (IFL). Ovarian antibodies were detected in 27% of idiopathic POF patients by ELISA (not significantly different compared to POF patients with associated autoimmune disease; P < 0.0003 compared to controls) but only 7% of these patients were positive by IFL. In a further, pre-selected group of individuals, all positive for ovarian antibodies by IFL, 53% had measurable antibodies by ELISA. Some overlap was therefore demonstrated between the two techniques but many POF patients had ovarian antibodies detectable by only one method. Immunoblotting studies revealed that no consistent pattern of binding could be demonstrated for these patients. These results call into question the specificity of ovarian antibodies as a marker for autoimmune POF.